Free Trial
→ Your $29.97 book is free today (From Profits Run) (Ad)tc pixel Free ATPC Stock Alerts

Agape ATP (ATPC) Competitors

Agape ATP logo
$2.37 -0.29 (-10.90%)
Closing price 04:00 PM Eastern
Extended Trading
$2.53 +0.16 (+6.92%)
As of 06:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

ATPC vs. ACON, ADVB, MRAI, MGRX, and BRTX

Should you be buying Agape ATP stock or one of its competitors? The main competitors of Agape ATP include Aclarion (ACON), Advanced Biomed (ADVB), Marpai (MRAI), Mangoceuticals (MGRX), and Biorestorative Therapies (BRTX). These companies are all part of the "healthcare" industry.

How does Agape ATP compare to Aclarion?

Agape ATP (NASDAQ:ATPC) and Aclarion (NASDAQ:ACON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Agape ATP has a net margin of -149.90% compared to Aclarion's net margin of -9,517.11%. Agape ATP's return on equity of -9.91% beat Aclarion's return on equity.

Company Net Margins Return on Equity Return on Assets
Agape ATP-149.90% -9.91% -9.29%
Aclarion -9,517.11%-52.31%-49.79%

In the previous week, Aclarion had 4 more articles in the media than Agape ATP. MarketBeat recorded 4 mentions for Aclarion and 0 mentions for Agape ATP. Agape ATP's average media sentiment score of 0.00 equaled Aclarion'saverage media sentiment score.

Company Overall Sentiment
Agape ATP Neutral
Aclarion Neutral

0.0% of Agape ATP shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 2.0% of Agape ATP shares are owned by insiders. Comparatively, 0.8% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Agape ATP has a beta of -0.92, suggesting that its share price is 192% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agape ATP
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Aclarion
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Agape ATP has higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than Agape ATP, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agape ATP$1.52M1.56-$2.28M-$14.50N/A
Aclarion$80K97.79-$7.23M-$17.01N/A

Summary

Agape ATP beats Aclarion on 8 of the 12 factors compared between the two stocks.

How does Agape ATP compare to Advanced Biomed?

Agape ATP (NASDAQ:ATPC) and Advanced Biomed (NASDAQ:ADVB) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, dividends and earnings.

Agape ATP has a beta of -0.92, meaning that its stock price is 192% less volatile than the S&P 500. Comparatively, Advanced Biomed has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.

0.0% of Agape ATP shares are held by institutional investors. 2.0% of Agape ATP shares are held by insiders. Comparatively, 34.4% of Advanced Biomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Advanced Biomed had 2 more articles in the media than Agape ATP. MarketBeat recorded 2 mentions for Advanced Biomed and 0 mentions for Agape ATP. Advanced Biomed's average media sentiment score of 1.02 beat Agape ATP's score of 0.00 indicating that Advanced Biomed is being referred to more favorably in the news media.

Company Overall Sentiment
Agape ATP Neutral
Advanced Biomed Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agape ATP
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Advanced Biomed
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Advanced Biomed has a net margin of 0.00% compared to Agape ATP's net margin of -149.90%. Advanced Biomed's return on equity of 92.11% beat Agape ATP's return on equity.

Company Net Margins Return on Equity Return on Assets
Agape ATP-149.90% -9.91% -9.29%
Advanced Biomed N/A 92.11%58.03%

Agape ATP has higher revenue and earnings than Advanced Biomed. Agape ATP is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agape ATP$1.52M1.56-$2.28M-$14.50N/A
Advanced BiomedN/AN/A-$3.26M$3.801.63

Summary

Advanced Biomed beats Agape ATP on 9 of the 12 factors compared between the two stocks.

How does Agape ATP compare to Marpai?

Agape ATP (NASDAQ:ATPC) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, Marpai's average media sentiment score of 1.08 beat Agape ATP's score of 0.00 indicating that Marpai is being referred to more favorably in the news media.

Company Overall Sentiment
Agape ATP Neutral
Marpai Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agape ATP
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Marpai
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Agape ATP has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Agape ATP, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agape ATP$1.52M1.56-$2.28M-$14.50N/A
Marpai$34.87M0.20-$28.75M-$0.95N/A

Marpai has a net margin of -85.70% compared to Agape ATP's net margin of -149.90%. Marpai's return on equity of 0.00% beat Agape ATP's return on equity.

Company Net Margins Return on Equity Return on Assets
Agape ATP-149.90% -9.91% -9.29%
Marpai -85.70%N/A -100.23%

Agape ATP has a beta of -0.92, indicating that its stock price is 192% less volatile than the S&P 500. Comparatively, Marpai has a beta of 4.38, indicating that its stock price is 338% more volatile than the S&P 500.

0.0% of Agape ATP shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 2.0% of Agape ATP shares are held by insiders. Comparatively, 46.1% of Marpai shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Marpai beats Agape ATP on 9 of the 13 factors compared between the two stocks.

How does Agape ATP compare to Mangoceuticals?

Agape ATP (NASDAQ:ATPC) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

Agape ATP has higher revenue and earnings than Mangoceuticals. Agape ATP is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agape ATP$1.52M1.56-$2.28M-$14.50N/A
Mangoceuticals$460K15.16-$20.64M-$2.56N/A

Agape ATP has a beta of -0.92, meaning that its stock price is 192% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.12, meaning that its stock price is 112% more volatile than the S&P 500.

0.0% of Agape ATP shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 2.0% of Agape ATP shares are held by company insiders. Comparatively, 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agape ATP
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Mangoceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Agape ATP's average media sentiment score of 0.00 equaled Mangoceuticals'average media sentiment score.

Company Overall Sentiment
Agape ATP Neutral
Mangoceuticals Neutral

Agape ATP has a net margin of -149.90% compared to Mangoceuticals' net margin of -4,536.70%. Agape ATP's return on equity of -9.91% beat Mangoceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Agape ATP-149.90% -9.91% -9.29%
Mangoceuticals -4,536.70%-109.38%-102.40%

Summary

Mangoceuticals beats Agape ATP on 6 of the 11 factors compared between the two stocks.

How does Agape ATP compare to Biorestorative Therapies?

Biorestorative Therapies (NASDAQ:BRTX) and Agape ATP (NASDAQ:ATPC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 0.0% of Agape ATP shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by insiders. Comparatively, 2.0% of Agape ATP shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Biorestorative Therapies has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Agape ATP has a beta of -0.92, meaning that its share price is 192% less volatile than the S&P 500.

In the previous week, Biorestorative Therapies had 1 more articles in the media than Agape ATP. MarketBeat recorded 1 mentions for Biorestorative Therapies and 0 mentions for Agape ATP. Biorestorative Therapies' average media sentiment score of 0.00 equaled Agape ATP'saverage media sentiment score.

Company Overall Sentiment
Biorestorative Therapies Neutral
Agape ATP Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biorestorative Therapies
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Agape ATP
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Agape ATP has higher revenue and earnings than Biorestorative Therapies. Agape ATP is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biorestorative Therapies$359.70K14.58-$14.24M-$1.59N/A
Agape ATP$1.52M1.56-$2.28M-$14.50N/A

Agape ATP has a net margin of -149.90% compared to Biorestorative Therapies' net margin of -3,956.11%. Agape ATP's return on equity of -9.91% beat Biorestorative Therapies' return on equity.

Company Net Margins Return on Equity Return on Assets
Biorestorative Therapies-3,956.11% -430.91% -203.61%
Agape ATP -149.90%-9.91%-9.29%

Summary

Biorestorative Therapies beats Agape ATP on 7 of the 12 factors compared between the two stocks.

Get Agape ATP News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATPC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATPC vs. The Competition

Export
MetricAgape ATPMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$2.37M$7.87B$6.18B$12.29B
Dividend YieldN/A2.45%2.78%5.25%
P/E Ratio-0.16124.3828.7027.27
Price / Sales1.567.67506.8864.14
Price / CashN/A17.0443.3053.97
Price / Book0.113.5010.006.82
Net Income-$2.28M$223.69M$3.54B$332.87M
7 Day PerformanceN/AN/AN/A0.09%
1 Month Performance-14.75%8.18%4.67%7.37%
1 Year Performance-96.97%2.21%40.47%41.10%

Agape ATP Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ATPC
Agape ATP
0.5154 of 5 stars		$2.37
-10.9%		N/A-96.9%$2.37M$1.52MN/A40
ACON
Aclarion
0.127 of 5 stars		$3.26
-3.3%		N/A-56.2%$7.43M$80KN/A7
ADVB
Advanced Biomed
0.5644 of 5 stars		$5.30
flat		N/AN/A$7.23MN/A1.3940
MRAI
Marpai
N/A$0.24
-7.0%		N/A-75.7%$6.08M$34.87MN/A150
MGRX
Mangoceuticals
0.6953 of 5 stars		$0.33
-7.9%		N/A-80.6%$5.63M$460KN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ATPC) was last updated on 5/8/2026 by MarketBeat.com Staff.
From Our Partners
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
The Death of the Nasdaq?
The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...
Chaikin Analytics | Sponsoredtc pixel
"Computers are about to become obsolete" - George Gilder. Here’s why.
George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...
Eagle Publishing | Sponsoredtc pixel
I’m sounding the alarm
Meta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...
Porter & Company | Sponsoredtc pixel
Nobody's Asking Where The SpaceX Money Comes From
When SpaceX goes public, fund managers will sell existing portfolio holdings to fund the move. Trillions in as...
Americas Gold Company | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel